The first BCMA-targeting antibody-drug conjugate for appropriate patients with relapsed/refractory multiple myeloma

BLENREP is composed of a humanized anti-BCMA monoclonal antibody conjugated to the cytotoxic payload MMAF by a protease-resistant linker.1,2

BLENREP specifically binds to B-cell maturation antigen (BCMA), a cell-surface protein expressed on myeloma cells, late-stage B cells, and plasma cells.1,3

A multimodal mechanism of action


Delivers cytotoxic payload1

Disrupts the microtubule network1

Engineered for enhanced ADCC and ADCP1,2

Image Showing BLENREP 3 Mechanisms of Action

BLENREP may have an effect on normal cells.1,2

Image of BLENREP Mechanism of Action: Specifically binds to BCMA

Specifically binds to BCMA:

Upon binding to BCMA on the cell surface, BLENREP is then internalized and releases a cytotoxin, mafodotin.1,2

Image of BLENREP Mechanism of Action: Cytotoxic Payload Delivery

Delivers a cytotoxic payload:

Mafodotin, a potent microtubule disruptor, prevents multiple myeloma cells from dividing, leading to apoptosis.1,4

Image of BLENREP Mechanism of Action: Enhanced Immune-Mediated Actions

Enhances immune-mediated actions:

BLENREP has an afucosylated antibody that enhances recruitment and activation of immune effector cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).1-3